[go: up one dir, main page]

MA31135B1 - Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. - Google Patents

Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Info

Publication number
MA31135B1
MA31135B1 MA31763A MA31763A MA31135B1 MA 31135 B1 MA31135 B1 MA 31135B1 MA 31763 A MA31763 A MA 31763A MA 31763 A MA31763 A MA 31763A MA 31135 B1 MA31135 B1 MA 31135B1
Authority
MA
Morocco
Prior art keywords
wnt
diagnosis
treatment
mediated disorders
antagonists
Prior art date
Application number
MA31763A
Other languages
Arabic (ar)
English (en)
Inventor
James A Ernst
Paul Polakis
Bonnee Rubinfeld
Almeida Venita I De
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31135B1 publication Critical patent/MA31135B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention concerne des antagonistes de wnt chimères comprenant un composant de domaine frz dérivé d'une protéine frizzled, une protéine connexe frizzled secrétée ou une protéine ror et un composant d'immunoglobuline fc, et leur utilisation dans le traitement et la détection aux fins de diagnostic d'une signalisation wnt cellulaire et de troubles à médiation wnt, dont le cancer
MA31763A 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. MA31135B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20
PCT/US2007/077845 WO2008031009A2 (fr) 2006-09-08 2007-09-07 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles à médiation wnt

Publications (1)

Publication Number Publication Date
MA31135B1 true MA31135B1 (fr) 2010-02-01

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31763A MA31135B1 (fr) 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Country Status (19)

Country Link
US (5) US7947277B2 (fr)
EP (1) EP2061495A2 (fr)
JP (1) JP2010504081A (fr)
KR (1) KR20090060334A (fr)
AR (1) AR062709A1 (fr)
AU (1) AU2007292242A1 (fr)
BR (1) BRPI0714751A2 (fr)
CA (1) CA2662041A1 (fr)
CL (1) CL2007002609A1 (fr)
CR (1) CR10699A (fr)
IL (1) IL197240A0 (fr)
MA (1) MA31135B1 (fr)
MX (1) MX2009002522A (fr)
NO (1) NO20091413L (fr)
PE (3) PE20081217A1 (fr)
RU (1) RU2009113023A (fr)
SG (2) SG174100A1 (fr)
TW (1) TW200819463A (fr)
WO (1) WO2008031009A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006308870B2 (en) * 2005-10-31 2012-08-16 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
US20100260785A1 (en) * 2007-12-13 2010-10-14 Gabriela Saborio SARP-1 Fusion Proteins and Uses Thereof
CN102027374A (zh) 2008-04-30 2011-04-20 霍夫曼-拉罗奇有限公司 Sfrp-3在评价心力衰竭中的用途
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
US7982013B2 (en) 2008-09-26 2011-07-19 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
EP2343080B1 (fr) * 2008-09-30 2017-11-08 Kyowa Hakko Kirin Co., Ltd. COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER DES MALADIES DES OS COMPRENANT UNE PROTÉINE COMPRENANT UN DOMAINE EXTRACELLULAIRE RICHE EN CYSTÉINE DE TYPE Frizzled1, Frizzled2 ET Frizzled7 et Fc PROTÉINE
WO2010124188A1 (fr) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps anti-ror1 humain
WO2010132532A1 (fr) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps réagissant à la surface des lymphocytes b
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2012006027A1 (fr) * 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Domaines extracellulaires fzd8 et molécules de fusion au domaine extracellulaire fzd8 et traitements les utilisant
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
US20120100562A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
AU2011329854B2 (en) * 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
EP2646469B1 (fr) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps ror1 chimériques lapin/humain
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
EP2725101B1 (fr) 2011-06-21 2017-09-27 Kyowa Hakko Kirin Co., Ltd. Protéine comprenant une forme tronquée d'une protéine à domaine extracellulaire de frizzled 2, et composition pharmaceutique pour le traitement de maladies osseuses qui comprend ladite protéine
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
EP4616914A3 (fr) * 2012-02-20 2025-11-19 IPC Research, LLC Polypeptides se liant au complément humain c5
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
US9957330B2 (en) * 2012-12-19 2018-05-01 Affibody Ab Polypeptides
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TW201610168A (zh) 2013-12-02 2016-03-16 安可美德藥物股份有限公司 與Ｗｎｔ途徑抑制劑有關之預測性生物標記之鑑別
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
KR101572606B1 (ko) 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
WO2016126054A1 (fr) 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation
WO2017165398A1 (fr) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions et méthodes pour inhiber la signalisation de wnt
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
US12252515B2 (en) 2018-01-16 2025-03-18 Children's Medical Center Corporation Compositions and methods for inhibiting Wnt signaling
US20230192846A1 (en) * 2019-11-18 2023-06-22 The Regents Of The University Of California Anti-ror-2 antibodies and methods of use
JP2023503615A (ja) * 2019-11-26 2023-01-31 シーダーズ－サイナイ メディカル センター 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法
WO2025058052A1 (fr) * 2023-09-14 2025-03-20 国立大学法人神戸大学 Procédé de criblage de matériau pour inhiber l'exacerbation de cellules de glioblastome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2664797A (en) * 1996-04-12 1997-11-07 Board Of Trustees Of The Leland Stanford Junior University Wnt receptor compositions and methods
US6433155B1 (en) * 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2001272974A1 (en) 2000-06-21 2002-01-02 Incyte Genomics, Inc. Human receptors
US7413873B2 (en) * 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
AU2002308557A1 (en) 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
AU2002317105A1 (en) 2001-07-05 2003-01-21 University Of British Columbia Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
WO2003009814A2 (fr) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
US20040247593A1 (en) * 2002-10-04 2004-12-09 Regents Of The University Of California, Methods for treating cancer by inhibiting Wnt signaling
US20040171559A1 (en) * 2002-12-06 2004-09-02 Irving Weissman Protection of stem cells from cytotoxic agents by modulation of beta-catenin signaling pathways
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20050096263A1 (en) * 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
WO2006036175A2 (fr) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines wnt et detection et traitement du cancer
CA2580780A1 (fr) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines dites "frazzled" et detection et traitement du cancer
EP1805519B1 (fr) 2004-09-21 2013-11-06 Rhode Island Hospital Protéines wnt et détection et traitement du cancer
WO2006055635A2 (fr) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
SG174101A1 (en) 2011-09-29
WO2008031009A2 (fr) 2008-03-13
US20170349639A1 (en) 2017-12-07
US20110311534A1 (en) 2011-12-22
SG174100A1 (en) 2011-09-29
BRPI0714751A2 (pt) 2014-06-24
TW200819463A (en) 2008-05-01
MX2009002522A (es) 2009-06-19
AR062709A1 (es) 2008-11-26
CR10699A (es) 2009-07-10
AU2007292242A1 (en) 2008-03-13
WO2008031009A3 (fr) 2009-07-02
US7947277B2 (en) 2011-05-24
PE20081217A1 (es) 2008-09-24
US20080299136A1 (en) 2008-12-04
JP2010504081A (ja) 2010-02-12
CL2007002609A1 (es) 2008-04-18
NO20091413L (no) 2009-06-08
RU2009113023A (ru) 2010-10-20
US20120141481A1 (en) 2012-06-07
KR20090060334A (ko) 2009-06-11
US20100266593A1 (en) 2010-10-21
IL197240A0 (en) 2011-08-01
PE20120806A1 (es) 2012-07-25
CA2662041A1 (fr) 2008-03-13
EP2061495A2 (fr) 2009-05-27
PE20120807A1 (es) 2012-07-26

Similar Documents

Publication Publication Date Title
MA31135B1 (fr) Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
EP4103233A4 (fr) Épitopes de lymphocytes t et compositions associées utiles dans la prévention, le diagnostic et le traitement de la covid-19
FR21C1004I2 (fr) Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe
MA44936A1 (fr) Méthodes de diagnostic et de traitement du cancer
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA45801B1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
MA30632B1 (fr) Anticorps humanisé
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1913388A4 (fr) Methodes et compositions pour le diagnostic et la surveillance d'une maladie cardiovasculaire atherosclereuse
EP2057466A4 (fr) Méthodes et compositions pour le traitement et le diagnostic de l'encéphalite auto-immune ou de l'épilepsie
EP1678195A4 (fr) Techniques et compositions pour le diagnostic et le traitement de la leucemie lymphocytaire chronique des cellules beta
MA30868B1 (fr) Derives de 2-aminocarbonyl-pyridine
MA30041B1 (fr) Immunoglobulines
EP1815872A4 (fr) Composition pour le diagnostic de maladies associees aux amyloides
EP1644532A4 (fr) Genes egr en tant que cibles pour le diagnostic et le traitement de la schizophrenie
DE602005011316D1 (de) Verfahren zur diagnose und behandlung von morbus crohn
Collins et al. Direct immunofluoresence in vasculitic neuropathy: specificity of vascular immune deposits
WO2003104761A3 (fr) Mesure de peptides de melanocortine et utilisations correspondantes